Raymond James & Associates Karuna Therapeutics, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$161.01 - $317.85 $65,692 - $129,682	-408 Reduced 16.99%	1,993 $630,000
Q3 2023 Oct 24, 2023	SELL	$164.66 - $218.08 $26,510 - $35,110	-161 Reduced 6.28%	2,401 $405,000
Q2 2023 Jul 25, 2023	SELL	$176.32 - $240.22 $92,568 - $126,115	-525 Reduced 17.01%	2,562 $555,000
Q1 2023 Apr 14, 2023	SELL	$161.33 - $204.36 $483 - $613	-3 Reduced 0.1%	3,087 $560,000
Q4 2022 Feb 08, 2023	SELL	$191.53 - $236.82 $5,171 - $6,394	-27 Reduced 0.87%	3,090 $607,000
Q3 2022 Oct 25, 2022	SELL	$123.79 - $277.42 $4,085 - $9,154	-33 Reduced 1.05%	3,117 $701,000
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $214,063 - $326,505	-2,278 Reduced 41.97%	3,150 $399,000
Q1 2022 May 11, 2022	SELL	$98.9 - $132.37 $8,010 - $10,721	-81 Reduced 1.47%	5,428 $688,000
Q4 2021 Feb 08, 2022	SELL	$110.64 - $159.4 $3,208 - $4,622	-29 Reduced 0.52%	5,509 $722,000
Q3 2021 Nov 02, 2021	SELL	$101.2 - $125.87 $18,418 - $22,908	-182 Reduced 3.18%	5,538 $677,000
Q2 2021 Aug 11, 2021	SELL	$107.45 - $135.95 $1,934 - $2,447	-18 Reduced 0.31%	5,720 $652,000
Q1 2021 May 14, 2021	SELL	$95.46 - $133.08 $668 - $931	-7 Reduced 0.12%	5,738 $690,000
Q4 2020 Feb 12, 2021	SELL	$75.23 - $109.23 $17,227 - $25,013	-229 Reduced 3.83%	5,745 $584,000
Q3 2020 Nov 04, 2020	SELL	$71.31 - $109.74 $927 - $1,426	-13 Reduced 0.22%	5,974 $462,000
Q2 2020 Jul 28, 2020	BUY	$62.14 - $117.21 $146,526 - $276,381	2,358 Added 64.98%	5,987 $667,000
Q1 2020 Apr 21, 2020	SELL	$60.41 - $115.92 $210,287 - $403,517	-3,481 Reduced 48.96%	3,629 $261,000
Q4 2019 Feb 12, 2020	BUY	$11.44 - $123.99 $81,338 - $881,568	7,110 New	7,110 $536,000

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account